Lonza Inc. and BioWa Sign License Agreements with FivePrime Therapeutics, Inc. for Use of Their POTELLIGENT® CHOK1SV Cell Line for Therapeutic Antibody Development
6/13/2012 10:25:54 AM
More...
|
arGEN-X Announces Non-exclusive License with BioWa for Potelligent® Technology
7/26/2011 11:43:41 AM
More...
|
arGEN-X Announces Non-Exclusive License With BioWa for POTELLIGENT® Technology
7/26/2011 9:43:21 AM
More...
|
ImmunoCellular Therapeutics, Ltd and BioWa Announce License for the Research and Development of Therapeutic Antibodies in Cancer
6/2/2011 10:14:36 AM
More...
|
Oxford BioTherapeutics Licenses BioWa's POTELLIGENT(R) Technology for the Research and Development of its Therapeutic Antibodies in Cancer
4/6/2011 7:40:13 AM
More...
|
KaloBios Pharmaceuticals, Inc. Selects POTELLIGENT(R) CHOK1SV Cell Line for the Research, Development and Manufacture of Humaneered(TM) Antibodies
2/8/2011 9:06:25 AM
More...
|
Daiichi Sankyo, Inc. (D4S.F) Selects POTELLIGENT(R) CHOK1SV Cell Line for the Research, Development and Manufacture of Recombinant Antibodies
7/26/2010 10:24:25 AM
More...
|
BioWa Announces Expansion of Licenses to GlaxoSmithKline (GSK)
6/23/2010 10:02:25 AM
More...
|
BioWa and NKT Therapeutics Inc. Announce Licensing of BioWa's POTELLIGENT(R) Technology For Use in Antibody Research and Development
10/21/2009 9:34:57 AM
More...
|
BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA (MKGAF.PK)
7/15/2009 8:48:45 AM
More...
|
|